Mark Neumann - Nov 6, 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Commercial Officer
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Nov 6, 2023
Transactions value $
-$1,717,661
Form type
4
Date filed
11/8/2023, 05:31 PM
Previous filing
Aug 9, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $640K +26.8K +59.01% $23.94 72.1K Nov 6, 2023 Direct
transaction ITCI Common Stock Sale -$1.5M -26.8K -37.11% $55.98 45.3K Nov 6, 2023 Direct F1
transaction ITCI Common Stock Sale -$860K -15.6K -34.49% $55.02 29.7K Nov 6, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -26.8K -100% $0.00* 0 Nov 6, 2023 Common Stock 26.8K $23.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.79 to $56.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.76 to $55.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 All shares underlying this option have vested.